Standard Biotools Inc. · NASDAQ:LAB
Standard Biotools — Q1 2023 Earnings Presentation
19 slides from Standard Biotools's earnings presentation, May 9, 2023
Slide 1: Unleashing tools to accelerate breakthroughs in human health
Unleashing tools to accelerate breakthroughs in human health™
Slide 2: First Quarter 2023 Financial Results
FIRST QUARTER 2023 FINANCIAL RESULTS May 9, 2023 Standard BioTools
Slide 3: Legal Information
Legal Information Forward-looking statements Non-GAAP financial information This presentation and the accompanying oral presentation forward-looking statements within the Standard BioTools has presented certain financial information in accordance with U.S. GAAP and also meaning of the Private Securi
Slide 4: CEO Commentary
CEO Commentary Michael Egholm, PhD Standard BioTools
Slide 5: Investment Highlights
Investment Highlights Platform Strategic M&A Create a diversified, innovation- focused Execute on highly strategic M&A life science tools company serving the across a broad target universe leveraging pharma research markets existing infrastructure Top-Grade Team Access to Capital World class team of
Slide 6: Progress Against Strategic Objectives
Progress Against Strategic Objectives 1 Return to Growth 2 Improve Operating Discipline 3 M&A Core Product and Service Revenue 1Q23 4Q22 ∆ 30,000,000 Product & Service 46.6% 40.9% 567 bp 2% Margin: GAAP 25,000,000 12% Product & Service 60.9% 52.9% 792 bp 20,000,000 Margin: Non-GAAP 15,000,000 (21%)
Slide 7: Proteomics
Proteomics Proteomics Revenues 16,000,000 12% 14,000,000 12,000,000 NextGen Features Robust roadmap 10,000,000 • 5X faster • More markers 8,000,000 16% • 40 slides per day • Higher resolution 3% 17% 6,000,000 • Improved workflow • Faster speed 4,000,000 • 40+ simultaneous • Smaller form factor 2,000
Slide 8: Genomics
Genomics Genomics Revenues X9™ High-Throughput Genomics System and IFC Consumables 12,000,000 Focus on (12%) 10,000,000 profitability, decline was 8,000,000 9% expected due to 6,000,000 (55%) product line 4,000,000 rationalization (1%) 2,000,000 and headcount 0 reductions Instruments Consumables Ser
Slide 9: First Quarter 2023 Financial Results
First Quarter 2023 Financial Results Vikram Jog, CFO Standard BioTools
Slide 10: Q1 2023 vs Q1 2022 Revenue
Q1 2023 vs Q1 2022 Revenue 1Q23/ 2022 2023 1Q22 Highlights (in $ millions) Q1 Q1 • Core product and service revenue grew 1.8% Proteomics Instruments 4.4 4.5 2.9% • Proteomics grew 12.3% Consumables 4.8 5.5 16.4% Service 4.4 5.2 17.2% Total Proteomics 12.3% • Genomics revenues declined 13.5 15.2 12.0
Slide 11: Selected Financial Information for 1Q22, 4Q22, 1Q23
Selected Financial Information for 1Q22, 4Q22, 1Q23 Selected Financial Statement Data (a) 2022 2023 1Q23/ 1Q23/ $ millions 1Q22 4Q22 Income Statement Q1 Q4 Q1 Product & Service margin GAAP 45.4% 40.9% 46.6% 117 bp 567 bp Non-GAAP 58.5% 52.9% 60.9% 236 bp 792 bp Operating Expenses Highlights: GAAP 39
Slide 12: Outlook for 2023
Outlook for 2023 2023 Outlook 2022 2023 Core Product and Service Revenue $94.5M Flat to moderately higher Product and Service Margin (GAAP) 36.7% 52% - 55% by 4Q23 Product and Service Margin (Non-GAAP) 50.2% 65% - 68% by 4Q23 Operating Expenses (GAAP) $153.3M $118M - $123M Operating Expenses (Non-GA
Slide 13: Unleashing tools to accelerate breakthroughs in human health
Unleashing tools to accelerate breakthroughs in human health™
Slide 14: Q1 2023 Supplemental Financial Information
Q1 2023 | Supplemental Financial Information May 9, 2023 Standard BioTools
Slide 15: Reconciliation of Total Revenue (GAAP) to Core Revenue
Reconciliation of Total Revenue (GAAP) to Core Revenue 15
Slide 16: Reconciliation of GAAP to Non-GAAP Product and Service Margin and Operating Expenses
Reconciliation of GAAP to Non-GAAP Product and Service Margin and Operating Expenses 16
Slide 17: Reconciliation of GAAP to Non-GAAP Loss From Operations
Reconciliation of GAAP to Non-GAAP Loss From Operations 17
Slide 18: Trademarks notice
™ Standard BioTools, the Standard BioTools logo, Fluidigm, the Fluidigm logo, “Unleashing tools to accelerate breakthroughs in human health,” Hyperion, Hyperion XTi, XTi, and X9 are trademarks and/or registered trademarks of Standard BioTools Inc. (f.k.a. Fluidigm Corporation) or its affiliates in t
Slide 19: Unleashing tools to accelerate breakthroughs in human health
Unleashing tools to accelerate breakthroughs in human health™ Standard BioTools